Guo Xiaotong, Lin Lede, Qiu Xiaohua, Tian Meng, Zhu Jiang
Department of Thoracic Oncology, West China Hospital, West China Medical Center, Sichuan University, Chengdu, China.
Laboratory of Reconstructive Urology, Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Front Psychiatry. 2022 Nov 23;13:950787. doi: 10.3389/fpsyt.2022.950787. eCollection 2022.
To investigate the effect of clinical trials on anxiety, depression, and the quality of life experienced by the family caregivers (FCs) of cancer patients.
We screened the FCs of patients who were participating in clinical trials and FCs of patients who were not participating in clinical trials [group FCs-GCP (FG) and group FCs-non-GCP (FNG) at Cancer Center of West China Hospital]. We assessed the anxiety, depression, and quality of life of the FCs using the Hospital Anxiety and Depression Scale and SF-12. The demographic characteristics of FCs and patients were analyzed.
The prevalences of anxiety and depression showed no significant difference between FG and FNG (46.3 vs. 51.5%, = 0.604; 36.6 vs. 51.5%, = 0.131, respectively). Physical Component Scores (PCS) were 48.87 ± 7.67 for FG and 48.01 ± 8.12 for FNG ( = 0.618) while Mental Component Scores (MCS) were 48.92 ± 7.78 and 44.89 ± 11.42, respectively ( = 0.031). The anxiety of FCs was positively associated with patients' advanced disease (HR 4.292 [1.409, 13.072], = 0.010) and initial treatment (HR 3.105 [1.014, 9.515], = 0.047). Depression was positively related to advanced disease (HR 3.347 [1.140, 9.832], = 0.028), and negatively related to patients participating in clinical trials (HR 0.421 [0.180, 0.985], = 0.046) and the education degree of FCs (HR 0.355 [0.149, 0.843], = 0.019). MCS was positively associated with patients participating in clinical trials (β = 5.067, 95% CI [0.817, 9.317], = 0.020) and negatively associated with advanced disease (β = -8.055, 95% CI [-19.804, 6.528], = 0.002).
The FCs of the cancer patients who participated in clinical trials showed a comparable worrying situation of anxiety and depression to the FCs of regular cancer patients. This indicates that more concern and attention should be given to this population, and further study on them is warranted.
探讨临床试验对癌症患者家庭照顾者（FCs）焦虑、抑郁及生活质量的影响。
我们筛选了正在参加临床试验的患者的FCs以及未参加临床试验的患者的FCs[华西医院癌症中心的FCs-GCP组（FG）和FCs-非GCP组（FNG）]。我们使用医院焦虑抑郁量表和SF-12评估FCs的焦虑、抑郁及生活质量。分析了FCs和患者的人口统计学特征。
FG组和FNG组焦虑和抑郁的患病率无显著差异（分别为46.3%对51.5%，P = 0.604；36.6%对51.5%，P = 0.131）。FG组的身体成分得分（PCS）为48.87±7.67，FNG组为48.01±8.12（P = 0.618），而心理成分得分（MCS）分别为48.92±7.78和44.89±11.42（P = 0.031）。FCs的焦虑与患者的晚期疾病呈正相关（HR 4.292[1.409，13.072]，P = 0.010）和初始治疗呈正相关（HR 3.105[1.014，9.515]，P = 0.047）。抑郁与晚期疾病呈正相关（HR 3.347[1.140，9.832]，P = 0.028），与参加临床试验的患者呈负相关（HR 0.421[0.180，0.985]，P = 0.046）以及与FCs的教育程度呈负相关（HR 0.355[0.149，0.843]，P = 0.019）。MCS与参加临床试验的患者呈正相关（β = 5.067，95%CI[0.817，9.317]，P = 0.020），与晚期疾病呈负相关（β = -8.055，95%CI[-19.804，6.528]，P = 0.002）。
参加临床试验的癌症患者的FCs在焦虑和抑郁方面的令人担忧情况与普通癌症患者的FCs相当。这表明应给予这一人群更多关注，对他们进行进一步研究是有必要的。
